FDA's ability to monitor and ensure the safety of drugs and medical devices after they appear on the market has been the subject of great scrutiny lately. As OMB Watch has reported, Congress and others have been critical of the agency for failing to conduct post-market safety studies. There are plenty of ideas for how the agency can improve their practices. Legislation is floating on Capitol Hill to beef up FDA funding and authority. Today, with the realization that those solutions are months off, FDA took a good step to improve the process in the near term. FDA has launched a webpage where the public can monitor the progress of post-market studies on medical devices. This is certain to hold the FDA more accountable to the American people. It also improves the transparency of the agency's actions which are often criticized for being too subject to industry influence. Reg•Watch hopes FDA expands this transparency to post-market studies on drugs as well.